Generic Name: eculizumab
Brand Name: Soliris
Manufacturer: Alexion Pharma Canada Corp.
Indications: generalized Myasthenia Gravis (gMG)
Manufacturer Requested Reimbursement Criteria1:
Soliris is indicated in adult patients with generalized Myasthenia Gravis (gMG).
Submission Type: New Indication
Project Status: Pending
Call For Patient Input: March 1, 2019
Patient Input Closed: April 22, 2019
Anticipated Date: April 3, 2019
Fee Schedule: Pending
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.